Mrs Ngozi Okafor Eyong, | |
702 15th St Ne, Washington, DC 20002-4508 | |
(202) 388-8500 | |
Not Available |
Full Name | Mrs Ngozi Okafor Eyong |
---|---|
Gender | Female |
Speciality | Counselor |
Location | 702 15th St Ne, Washington, District Of Columbia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1881037299 | NPI | - | NPPES |
LC50082059 | Other | DC | BOARD OF SOCIAL WORK |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164X00000X | Licensed Vocational Nurse | 50329 (District Of Columbia) | Secondary |
101Y00000X | Counselor | LC50082059 (District Of Columbia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Ngozi Okafor Eyong, 702 15th St Ne, Washington, DC 20002-4508 Ph: (202) 388-8500 | Mrs Ngozi Okafor Eyong, 702 15th St Ne, Washington, DC 20002-4508 Ph: (202) 388-8500 |
News Archive
A research team led by scientists at The University of Texas Medical School at Houston has identified a defective gene that affects vascular smooth-muscle cells in people who suffer from hereditary thoracic aortic disease, which can kill victims with little warning in the prime of their lives.
NewYork-Presbyterian Hospital has two new treatment options for patients with brain tumors and other cancers - a next-generation radiosurgical Gamma Knife and linear accelerator.
The work deepens understanding of an autistic brain's function and may one day inform new treatment approaches and augment how teachers interact with their autistic students.
Patients who suffer from chronic rhinosinusitis (CRS) also tend to suffer from other chronic illnesses, like asthma, hypertension, and arthritis.
Rules-Based Medicine, Inc. (RBM) today announced the Cancer Prevention and Research Institute of Texas (CPRIT) has granted it a Company Commercialization Award to expand and enhance the OncologyMAP™ program for discovery and development of novel diagnostic and prognostic cancer tests. The award of approximately $3 million will fund research and development to more than double the number of cancer-associated biomarker assays in RBM's new OncologyMAP™ product.
› Verified 2 days ago